サマリー

世界の線維性疾患治療市場は、2023年から2030年の予測期間に6.0%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションです：
線維性疾患治療の世界市場、治療法別（投薬、臓器移植、酸素療法、その他）、用途別（特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他）、エンドユーザー別（病院、専門クリニック、学術・研究機関、その他）、流通チャネル（病院薬局、小売薬局、その他）、国（アメリカ、カナダ、メキシコ、ドミニカ共和国、ジャマイカ、パナマ ドイツ、フランス、U.K、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、ハンガリー、リトアニア、オーストリア、アイルランド、ノルウェー、ポーランド、欧州、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、台湾 アジア太平洋、ブラジル、エクアドル、チリ、コロンビア、ヴェネズエラ、アルゼンチン、ペルー、クラサオ、パラグアイ、ウルグアイ、トリニダード・トバコ、南米、南アフリカ、サウジアラビア、U.A.E．エジプト、クウェート、バーレーン、イスラエル、中東・アフリカ地域) 産業動向と2030年までの予測

世界の線維性疾患治療市場の成長に寄与する主な要因として、以下のものが挙げられます：
- 線維性疾患の有病率の上昇
- たばこを吸う人の増加

市場プレイヤーの紹介
世界の線維性疾患治療市場の主要な市場プレイヤーの一部を以下に示します：
- Genentech, Inc.
- ベーリンガーインゲルハイムインターナショナルGmbH
- アッヴィー社（AbbVie Inc.
- レドックス・ファーマ・ピーエルシー
- ブリストル・マイヤーズ スクイブ・カンパニー
- ベルブルック研究所
- エンベダ・バイオサイエンス
- バイオMX
- ギリアド・サイエンシズ社（Gilead Sciences, Inc.
- キターバイオテック S.R.L.
- ヴェローナ・ファーマ・ピーエルシー
- アルパイン・イミューン・サイエンス
- インターセプト・ファーマシューティカルズ・インク
- ファーマクシス・リミテッド
- テバ・ファーマシューティカル・インダストリーズ・リミテッド
- サンド・インターナショナルGmbH
- アコードヘルスケア
- キャンバー・ファーマシューティカルズ・インク

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET 34
1.4 LIMITATIONS 36
1.5 MARKETS COVERED 36
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 TREATMENT TYPE LIFELINE CURVE 44
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.9 DBMR MARKET POSITION GRID 46
2.10 MARKET END USER COVERAGE GRID 47
2.11 VENDOR SHARE ANALYSIS 48
2.12 SECONDARY SOURCES 49
2.13 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
4.1 PORTER'S 5 FORCES 55
4.2 PESTEL ANALYSIS 56
5 EPIDEMIOLOGY 57
5.1 INCIDENCE OF ALL BY GENDER 57
5.2 TREATMENT RATE 57
5.3 MORTALITY RATE 57
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 58
5.5 PATIENT TREATMENT SUCCESS RATE 58
6 INDUSTRY INSIGHTS 59
6.1 PATENT ANALYSIS 59
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 59
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 59
6.4 KEY PRICING STRATEGIES 60
6.5 KEY PATIENT ENROLLMENT STRATEGIES 61
7 MERGERS AND ACQUISITIONS 63
7.1 LICENSING: 63
7.2 COMMERCIALIZATION AGREEMENTS 63
8 PIPELINE ANALYSIS 64
8.1 PHASE 1 64
8.2 PHASE 2 64
8.3 PHASE 3 64
9 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 65
9.1 FDA APPROVALS 65
9.2 EMA APPROVALS 66
10 MARKET OVERVIEW 67
10.1 DRIVERS 69
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 69
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 69
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 70
10.2 RESTRAINTS 70
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 70
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 70
10.3 OPPORTUNITIES 71
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 71
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 71
10.4 CHALLENGES 72
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 72
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 72
11 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 73
11.1 OVERVIEW 74
11.2 MEDICATION 76
11.2.1 INTEDANIB (OFEV) 77
11.2.2 PIRFENIDONE (ESBRIET) 77
11.3 ORGAN TRANSPLANTATION 77
11.4 OXYGEN THERAPY 78
11.5 OTHERS 79
12 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 80
12.1 OVERVIEW 81
12.2 IDIOPATHIC PULMONARY FIBROSIS 84
12.3 HEPATIC CIRRHOSIS 84
12.4 RENAL FIBROSIS 85
12.5 CUTANEOUS FIBROSIS 86
12.6 OTHERS 87
13 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY END USER 88
13.1 OVERVIEW 89
13.2 HOSPITALS 92
13.3 SPECIALTY CLINICS 93
13.4 ACADEMIC AND RESEARCH INSTITUTES 93
13.5 OTHERS 94
14 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 95
14.1 OVERVIEW 96
14.2 HOSPITAL PHARMACY 99
14.3 RETAIL PHARMACY 99
14.4 OTHERS 100
15 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY REGION 101
15.1 OVERVIEW 102
15.2 NORTH AMERICA 107
15.2.1 U.S. 113
15.2.2 CANADA 115
15.2.3 MEXICO 117
15.2.4 DOMINICAN REPUBLIC 119
15.2.5 JAMAICA 121
15.2.6 PANAMA 123
15.3 EUROPE 125
15.3.1 GERMANY 132
15.3.2 FRANCE 134
15.3.3 U.K. 136
15.3.4 ITALY 138
15.3.5 SPAIN 140
15.3.6 RUSSIA 142
15.3.7 TURKEY 144
15.3.8 NETHERLANDS 146
15.3.9 SWITZERLAND 148
15.3.10 HUNGARY 150
15.3.11 LITHUANIA 152
15.3.12 AUSTRIA 154
15.3.13 IRELAND 156
15.3.14 NORWAY 158
15.3.15 POLAND 160
15.3.16 REST OF EUROPE 162
15.4 ASIA-PACIFIC 163
15.4.1 JAPAN 170
15.4.2 CHINA 172
15.4.3 INDIA 174
15.4.4 SOUTH KOREA 176
15.4.5 AUSTRALIA 178
15.4.6 SINGAPORE 180
15.4.7 THAILAND 182
15.4.8 MALAYSIA 184
15.4.9 INDONESIA 186
15.4.10 PHILIPPINES 188
15.4.11 VIETNAM 190
15.4.12 TAIWAN 192
15.4.13 REST OF ASIA-PACIFIC 194
15.5 SOUTH AMERICA 195
15.5.1 BRAZIL 202
15.5.2 ECUADOR 204
15.5.3 CHILE 206
15.5.4 COLUMBIA 208
15.5.5 VENEZUELA 210
15.5.6 ARGENTINA 212
15.5.7 PERU 214
15.5.8 CURACAO 216
15.5.9 PARAGUAY 218
15.5.10 URUGUAY 220
15.5.11 TRINIDAD AND TOBAGO 222
15.5.12 REST OF SOUTH AMERICA 224
15.6 MIDDLE EAST AND AFRICA 225
15.6.1 SOUTH AFRICA 231
15.6.2 SAUDI ARABIA 233
15.6.3 U.A.E 235
15.6.4 EGYPT 237
15.6.5 KUWAIT 239
15.6.6 ISRAEL 241
15.6.7 BAHRAIN 243
15.6.8 REST OF MIDDLE EAST AND AFRICA 245
16 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 246
16.1 COMPANY SHARE ANALYSIS: GLOBAL 246
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 247
16.3 COMPANY SHARE ANALYSIS: EUROPE 248
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 249
17 SWOT ANALYSIS 250
18 COMPANY PROFILE 251
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 251
18.1.1 COMPANY SNAPSHOT 251
18.1.2 REVENUE ANALYSIS 251
18.1.3 COMPANY SHARE ANALYSIS 252
18.1.4 PRODUCT PORTFOLIO 252
18.1.5 RECENT DEVELOPMENTS 252
18.2 GENENTECH, INC. 253
18.2.1 COMPANY SNAPSHOT 253
18.2.2 COMPANY SHARE ANALYSIS 253
18.2.3 PRODUCT PORTFOLIO 254
18.2.4 RECENT DEVELOPMENTS 254
18.3 SANDOZ INTERNATIONAL GMBH 255
18.3.1 COMPANY SNAPSHOT 255
18.3.2 COMPANY SHARE ANALYSIS 255
18.3.3 PRODUCT PORTFOLIO 256
18.3.4 RECENT DEVELOPMENTS 256
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 257
18.4.1 COMPANY SNAPSHOT 257
18.4.2 REVENUE ANALYSIS 257
18.4.3 COMPANY SHARE ANALYSIS 258
18.4.4 PRODUCT PORTFOLIO 258
18.4.5 RECENT DEVELOPMENTS 258
18.5 ACCORD HEALTHCARE U.S. 259
18.5.1 COMPANY SNAPSHOT 259
18.5.2 COMPANY SHARE ANALYSIS 259
18.5.3 PRODUCT PORTFOLIO 260
18.5.4 RECENT DEVELOPMENTS 260
18.6 ABBVIE INC. 261
18.6.1 COMPANY SNAPSHOT 261
18.6.2 REVENUE ANALYSIS 261
18.6.3 PRODUCT PORTFOLIO 262
18.6.4 RECENT DEVELOPMENTS 262
18.7 ALPINE IMMUNE SCIENCES 263
18.7.1 COMPANY SNAPSHOT 263
18.7.2 REVENUE ANALYSIS 263
18.7.3 PRODUCT PORTFOLIO 264
18.7.4 RECENT DEVELOPMENTS 264
18.8 BELLBROOK LABS 265
18.8.1 COMPANY SNAPSHOT 265
18.8.2 PRODUCT PORTFOLIO 265
18.8.3 RECENT DEVELOPMENTS 265
18.9 BIOMX 266
18.9.1 COMPANY SNAPSHOT 266
18.9.2 REVENUE ANALYSIS 266
18.9.3 PRODUCT PORTFOLIO 267
18.9.4 RECENT DEVELOPMENTS 267
18.10 BRISTOL-MYERS SQUIBB COMPANY 268
18.10.1 COMPANY SNAPSHOT 268
18.10.2 REVENUE ANALYSIS 268
18.10.3 PRODUCT PORTFOLIO 269
18.10.4 RECENT DEVELOPMENTS 269
18.11 CAMBER PHARMACEUTICALS, INC. 270
18.11.1 COMPANY SNAPSHOT 270
18.11.2 PRODUCT PORTFOLIO 270
18.11.3 RECENT DEVELOPMENTS 270
18.12 ENVEDA 271
18.12.1 COMPANY SNAPSHOT 271
18.12.2 PRODUCT PORTFOLIO 271
18.12.3 RECENT DEVELOPMENTS 271
18.13 GILEAD SCIENCES, INC. 272
18.13.1 COMPANY SNAPSHOT 272
18.13.2 REVENUE ANALYSIS 272
18.13.3 PRODUCT PORTFOLIO 273
18.13.4 RECENT DEVELOPMENTS 273
18.14 INTERCEPT PHARMACEUTICALS, INC. 274
18.14.1 COMPANY SNAPSHOT 274
18.14.2 REVENUE ANALYSIS 274
18.14.3 PRODUCT PORTFOLIO 275
18.14.4 RECENT DEVELOPMENTS 275
18.15 KITHER BIOTECH S.R.L. 276
18.15.1 COMPANY SNAPSHOT 276
18.15.2 PRODUCT PORTFOLIO 276
18.15.3 RECENT DEVELOPMENTS 276
18.16 PHARMAXIS LTD 277
18.16.1 COMPANY SNAPSHOT 277
18.16.2 REVENUE ANALYSIS 277
18.16.3 PRODUCT PORTFOLIO 278
18.16.4 RECENT DEVELOPMENTS 278
18.17 REDX PHARMA PLC. 279
18.17.1 COMPANY SNAPSHOT 279
18.17.2 REVENUE ANALYSIS 279
18.17.3 PRODUCT PORTFOLIO 280
18.17.4 RECENT DEVELOPMENTS 280
18.18 VERONA PHARMA PLC 281
18.18.1 COMPANY SNAPSHOT 281
18.18.2 REVENUE ANALYSIS 281
18.18.3 PRODUCT PORTFOLIO 282
18.18.4 RECENT DEVELOPMENTS 282
19 QUESTIONNAIRE 283
20 RELATED REPORTS 286

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 64
TABLE 2 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 76
TABLE 3 GLOBAL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 4 GLOBAL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 77
TABLE 5 GLOBAL ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 6 GLOBAL OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 7 GLOBAL OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 8 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 83
TABLE 9 GLOBAL IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 10 GLOBAL HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 11 GLOBAL RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 12 GLOBAL CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 13 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 14 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 91
TABLE 15 GLOBAL HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 16 GLOBAL SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 17 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 18 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 19 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 20 GLOBAL HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 21 GLOBAL RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 22 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 23 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 24 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 111
TABLE 25 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 111
TABLE 26 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 111
TABLE 27 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 111
TABLE 28 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 112
TABLE 29 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 112
TABLE 30 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 31 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 32 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 113
TABLE 33 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 113
TABLE 34 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 113
TABLE 35 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 113
TABLE 36 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 114
TABLE 37 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 38 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 39 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 115
TABLE 40 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 115
TABLE 41 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 115
TABLE 42 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 115
TABLE 43 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 116
TABLE 44 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 116
TABLE 45 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 116
TABLE 46 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 117
TABLE 47 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 117
TABLE 48 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 117
TABLE 49 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 117
TABLE 50 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 118
TABLE 51 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 118
TABLE 52 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 53 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 119
TABLE 54 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 119
TABLE 55 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 119
TABLE 56 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 119
TABLE 57 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 120
TABLE 58 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
TABLE 59 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 120
TABLE 60 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 121
TABLE 61 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 121
TABLE 62 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 121
TABLE 63 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 121
TABLE 64 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 122
TABLE 65 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
TABLE 66 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 67 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 123
TABLE 68 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 123
TABLE 69 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 123
TABLE 70 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 123
TABLE 71 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 124
TABLE 72 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 124
TABLE 73 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 74 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 129
TABLE 75 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 129
TABLE 76 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 129
TABLE 77 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 130
TABLE 78 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 130
TABLE 79 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 130
TABLE 80 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 130
TABLE 81 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
TABLE 82 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 132
TABLE 83 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 132
TABLE 84 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 132
TABLE 85 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 132
TABLE 86 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 133
TABLE 87 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
TABLE 88 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 89 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 134
TABLE 90 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 134
TABLE 91 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 134
TABLE 92 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 134
TABLE 93 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 135
TABLE 94 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 135
TABLE 95 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 135
TABLE 96 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 136
TABLE 97 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 136
TABLE 98 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 136
TABLE 99 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 136
TABLE 100 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 137
TABLE 101 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 102 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 103 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 138
TABLE 104 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 138
TABLE 105 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 138
TABLE 106 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 138
TABLE 107 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 139
TABLE 108 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 139
TABLE 109 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 110 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 140
TABLE 111 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 140
TABLE 112 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 140
TABLE 113 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 140
TABLE 114 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 141
TABLE 115 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
TABLE 116 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 117 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 142
TABLE 118 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 142
TABLE 119 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 142
TABLE 120 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 142
TABLE 121 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 143
TABLE 122 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 143
TABLE 123 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 143
TABLE 124 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 144
TABLE 125 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 144
TABLE 126 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 144
TABLE 127 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 144
TABLE 128 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 145
TABLE 129 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 145
TABLE 130 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 131 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 146
TABLE 132 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 146
TABLE 133 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 146
TABLE 134 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 146
TABLE 135 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 147
TABLE 136 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
TABLE 137 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 147
TABLE 138 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 148
TABLE 139 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 148
TABLE 140 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 148
TABLE 141 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 148
TABLE 142 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 149
TABLE 143 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 149
TABLE 144 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 149
TABLE 145 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 150
TABLE 146 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 150
TABLE 147 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 150
TABLE 148 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 150
TABLE 149 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 151
TABLE 150 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 151
TABLE 151 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 152 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 152
TABLE 153 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 152
TABLE 154 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 152
TABLE 155 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 152
TABLE 156 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 153
TABLE 157 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 153
TABLE 158 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
TABLE 159 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 154
TABLE 160 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 154
TABLE 161 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 154
TABLE 162 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 154
TABLE 163 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 155
TABLE 164 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
TABLE 165 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
TABLE 166 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 156
TABLE 167 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 156
TABLE 168 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 156
TABLE 169 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 156
TABLE 170 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 157
TABLE 171 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 157
TABLE 172 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 173 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 158
TABLE 174 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 158
TABLE 175 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 158
TABLE 176 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 158
TABLE 177 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 159
TABLE 178 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 159
TABLE 179 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 159
TABLE 180 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 160
TABLE 181 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 160
TABLE 182 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 160
TABLE 183 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 160
TABLE 184 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 161
TABLE 185 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 161
TABLE 186 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 161
TABLE 187 REST OF EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 162
TABLE 188 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 167
TABLE 189 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 167
TABLE 190 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 168
TABLE 191 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 168
TABLE 192 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 168
TABLE 193 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 168
TABLE 194 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 169
TABLE 195 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
TABLE 196 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 170
TABLE 197 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 170
TABLE 198 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 170
TABLE 199 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 170
TABLE 200 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 171
TABLE 201 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 171
TABLE 202 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 171
TABLE 203 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 172
TABLE 204 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 172
TABLE 205 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 172
TABLE 206 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 172
TABLE 207 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 173
TABLE 208 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 173
TABLE 209 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 173
TABLE 210 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 174
TABLE 211 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 174
TABLE 212 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 174
TABLE 213 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 174
TABLE 214 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 175
TABLE 215 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 175
TABLE 216 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175